Grape Compound Piceatannol Shields Retinal Blood Vessels by Reprogramming Immune Cells

A natural polyphenol found in grapes, berries and red wine may offer a new line of defense against one of the world’s leading causes of blindness. In a study published in the Journal of Translational Medicine, a team of ophthalmology researchers in Suzhou, China, reports that piceatannol, a close structural relative of resveratrol, protects the delicate blood vessels of the retina in diabetic mice by calming overactive immune cells and preserving the molecular seals that keep the inner blood-retinal barrier intact. The work, led by Yuanyuan Tu and Manhui Zhu of the Lixiang Eye Hospital of Soochow University together with colleagues at the Second Affiliated Hospital of Soochow University, identifies a specific chemokine signaling axis as the molecular switch that the compound appears to flip.

Diabetic retinopathy is a devastating complication of diabetes, characterized by progressive damage to the microvascular network that nourishes the light-sensitive tissue at the back of the eye. For decades, clinicians have focused their attention on the blood vessels themselves, treating the leaky capillaries and abnormal new vessel growth with laser therapy, injections of anti-VEGF drugs, or surgery. But a growing body of evidence points to a quieter culprit: chronic neuroinflammation, driven in large part by microglia, the resident immune cells of the retina. When these cells become chronically activated in a high-glucose environment, they release a cocktail of pro-inflammatory cytokines that erode the structural and functional integrity of the retinal vasculature from the outside in.

The research team approached the problem with an unusually systematic strategy. Rather than testing piceatannol blindly, they combined network pharmacology with transcriptomic analysis to map the compound’s potential molecular targets against the gene signatures of diabetic retinopathy. The computational screen identified 159 overlapping targets shared between the polyphenol and the disease. Among these, one receptor rose to the top: C-C chemokine receptor type 5, or CCR5, a G protein-coupled receptor best known to immunologists for its role in directing immune cell traffic and, famously, as an entry co-receptor exploited by HIV.

Molecular docking studies predicted that piceatannol could bind directly to CCR5, and the researchers went on to validate that binding affinity experimentally. This mattered because the receptor’s ligand, the chemokine CCL5, was significantly upregulated in the diabetic retina. The picture that emerged was of a signaling cascade, CCL5 binding to CCR5 and triggering the pro-inflammatory transcription factor NF-κB, that could potentially be intercepted at its receptor by a dietary polyphenol. Single-cell and expression analyses added a crucial layer of specificity: CCR5 was found to be expressed predominantly in retinal microglia, placing the immune cells squarely at the center of the pathway.

To test the compound’s effects, the team built disease models at two scales. In the laboratory, they exposed microglia to high glucose concentrations to mimic the diabetic metabolic environment. In living animals, they induced diabetes in mice using streptozotocin, a chemical that destroys insulin-producing cells and produces sustained hyperglycemia. The results in the animals were striking. Mice treated with piceatannol showed restored retinal thickness, reduced formation of acellular capillaries, the ghost vessels that mark dead capillary segments in diabetic retinas, and attenuated vascular leakage, the pathological seepage of fluid and proteins that ultimately destroys vision.

The cellular mechanism behind these improvements centered on microglial polarization. Microglia, like their peripheral cousins the macrophages, can adopt broadly two functional states. The M1 phenotype is pro-inflammatory, unleashing tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6, along with inducible nitric oxide synthase, all of which batter neighboring tissue. The M2 phenotype is restorative, promoting tissue repair through markers such as arginase-1, interleukin-10 and transforming growth factor beta 1. In the diabetic retina, the balance tips decisively toward M1. Piceatannol treatment, the researchers found, inhibited microglial activation and M1 polarization, reduced the secretion of pro-inflammatory cytokines, and promoted the expression of M2-associated markers, all through modulation of the CCL5/CCR5/NF-κB signaling pathway.

The downstream consequences for blood vessels were equally telling. In vitro experiments using human retinal endothelial cells showed that when high glucose pushed co-cultured microglia into their inflammatory state, the endothelial cells suffered: the tight junction proteins zonula occludens-1 and Claudin-5, which zip adjacent endothelial cells together to form the inner blood-retinal barrier, were degraded. Piceatannol suppressed the high-glucose-induced M1 polarization of the microglia and, as a result, preserved the expression of these tight junction proteins. In other words, the compound’s vascular protection appears to be indirect, mediated through the immune cells rather than through a direct effect on the endothelium itself.

The team then put the CCR5 hypothesis to a rigorous causal test. Using small interfering RNA to knock down CCR5 expression, and separately employing pharmacological activation of the receptor, they confirmed that CCR5 sits at the center of the protective mechanism. When the receptor was silenced, piceatannol’s benefits were diminished or recapitulated by the knockdown itself; when the pathway was artificially activated, the compound’s protective effects were counteracted. This pattern of gain- and loss-of-function evidence strengthens the argument that the CCL5/CCR5/NF-κB axis is not merely correlated with the disease process but is functionally required for the drug’s action.

The significance of the work lies partly in its translational framing. Piceatannol is a naturally occurring stilbenoid, meaning it is already present in the human food supply and has been studied for anti-inflammatory and vascular-protective properties in other contexts. Demonstrating a concrete, mechanistically defined role in diabetic retinopathy raises the possibility of repurposing a well-characterized molecule for a condition that currently affects tens of millions of people worldwide. The network pharmacology approach also offers a template for how natural products with dozens of potential targets can be systematically triaged, using docking, transcriptomics and weighted gene co-expression network analysis to converge on the handful of targets that actually matter.

Substantial caveats remain before patients should expect a piceatannol-based therapy. The findings come from cell culture and streptozotocin-induced mouse models, which reproduce key features of diabetic retinopathy but do not capture the full complexity of human disease, which unfolds over decades of metabolic stress. Questions about bioavailability, dosing, retinal drug delivery and long-term safety in a diabetic population remain open, and the study was funded by Chinese national and municipal science programs without reported involvement of commercial drug development. Still, by pinpointing a druggable receptor on retinal microglia and showing that a food-derived polyphenol can restrain the inflammatory cascade that dismantles the blood-retinal barrier, the study adds a compelling new chapter to the growing recognition that diabetic blindness is as much an immunological disease as a vascular one.

Subject of Research: The role of piceatannol in modulating microglial polarization via the CCL5/CCR5/NF-κB axis to protect retinal endothelial cells in diabetic retinopathy

Article Title: Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis

Article References: Tu, Y., Guo, Y., Zhang, Y., Sun, H., Zhu, X., Shen, G., Gu, Y., Xie, L., Song, E., & Zhu, M. (2026). Piceatannol attenuates retinal endothelial cell dysfunction by modulating microglial polarization via the CCL5/CCR5/NF-κB axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08893-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08893-6

Keywords: diabetic retinopathy, piceatannol, microglial polarization, CCR5, CCL5, NF-κB, retinal endothelial cells, blood-retinal barrier, neuroinflammation, tight junctions, network pharmacology, resveratrol